CSI Market
Sign In | Register

Casi Pharmaceuticals inc (CASIF) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CASIF Annual Cash Flow →
Looking at cash flow data from Casi Pharmaceuticals inc through Dec 31 2024 provides insight into Dec 31 2025's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-48.06
Depreciation & amortization1.23
Amortization of Other Assets0.03
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-2.51
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets-0.01
Share-based Compensation3.00
Income (Loss) from Equity Method Investments-2.19
Financial Instruments and Foreign Currency Transaction-2.16
Amortization Of Intangible Assets And Held For Sale-
Reduction In Carrying Amount Of Right Of Use Assets-
Research And Development In Process Acquired-
Government Grant-
Equity Securities Fv Ni Unrealized Gain Loss-
Debt Securities Realized Gain Loss-
Equity Securities Fv Ni Gain Loss-
Income taxes-3.44
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-11.25
Increase (Decrease) in Accounts Payable, Trade-1.66
Increase (Decrease) in Accrued Liabilities6.39
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.01
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-20.75
Investing Activities
Capital Expenditures0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities Fv Ni-
Payments To Acquire Term Deposits-
Proceeds From Government Grant-
Receipt Of Repayment Of Convertible Note-
Proceeds From Extinguishment Of Investment In Convertible Loan-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments1.62
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.95
Financing Activities
Short-term debt Net1.00
Other borrowing transactions0.00
Long-term debt - borrowings5.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.68
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities11.25
Effect of exchange rate on cash flow0.71
Discontinued operations0.00
Free Cash Flow-20.74
Total Cash Flow-7.84
4 historic quarters locked

Sign in to unlock the full Casi Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About Casi Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-061632

Figures are derived from filed reports and may be restated. Historical data is subject to revision.